通泰合剂联合化疗治疗晚期大肠癌临床观察

许尤琪; 钱娟; 王倩

通泰合剂联合化疗治疗晚期大肠癌临床观察

1.
南京中医药大学第二附属医院，江苏南京 210017
2.
溧阳市中医院肿瘤科，常州溧阳 213300

计量
- 文章访问数: 902
- HTML全文浏览量: 2
- PDF下载量: 1130
- 被引次数: 0
出版历程
- 收稿日期: 2013-12-27
- 修回日期: 2014-01-12
- 刊出日期: 2014-03-10

Clinical Observation of Tongtai Decoction Combined with Chemotherapy in Treating Advanced Colorectal Cancer

1.
The Second Hospital of Nanjing University of Chinese Medicine, Nanjing, 210017, China
2.
Oncology, Liyang Municipal Hospital of Traditional Chinese Medicine, Liyang, 213300, China

摘要

摘要: 目的观察通泰合剂联合化疗治疗晚期大肠癌的临床疗效。方法应用通泰合剂联合化疗治疗晚期大肠癌20例(治疗组)与单纯化疗组20例(对照组)患者进行近期临床客观疗效、临床症状、生活状态的改变、肿瘤指标（CEA）、化疗不良反应的程度及化疗耐受性方面的比较。结果在肿瘤治疗效果的客观指标如近期客观疗效、血清CEA水平降低方面，2组差异无统计学意义（P>0.05），但在减轻化疗药物毒副反应、改善临床症状、提高生活质量、改善一般状况方面，治疗组有明显优势（P<0.05）。结论通泰合剂联合化疗能缓解晚期大肠癌患者化疗期间的毒副反应，改善患者临床症状，提高患者生活质量。
- 通泰合剂 /
- 化疗：晚期大肠癌
Abstract: OBJECTIVE To observe the clinical effects of Tongtai decoction combined with chemotherapy in treating advanced colorectal cancer. METHODS 40 cases were randomly divided into two groups: control group and treatment group with 20 cases in each. Treatment group was given Tongtai decoction combined with chemotherapy at the same time while control group was given chemotherapy only. We observed the clinical efficiency， change of tumor marker CEA， integration changes of symptoms， clinical symptoms before and after treatment， karnofsky score， adverse reactions and tolerability of chemotherapy. RESULTS The patients of two groups have shown no significant difference in objective curative effect and in reducing the value of serum CEA (P>0.05) . But the treatment group was superior to the control group in reducing the toxicity of chemotherapy，improving the clinical symptoms， improving quality of life and the general condition (P<0.05). CONCLUSION The combined treatment of Tongtai decoction with chemotherapy can effectively resolve clinical symptoms of patients with advanced colorectal cancer， lower toxicity during chemotherapy， and improve their quality of life.
- Tongtai decoction /
- chemotherapy

HTML全文

参考文献(7)

[1]	卫生部医政司.结直肠癌诊疗规范[J].中华胃肠外科杂志，2010，13(11):865-875.
[2]	The ministry of health department. Colorectal cancer diagnosis and treatment norms[J]. Chin J Gastrointestinal Surger， 2010， 13(11): 865-875.
[3]	Edge SB， Byrd DR， Compton CC， et al. AJCC Cancer Staging Manual[M]. 7th ed. New York: Springer， 2010:143-164.
[4]	中药新药临床研究指导原则[M].北京：中国医药科技出版社， 2002：362.
[5]	Guidelines for the Clinical Research of Chinese Medicine New Drugs[M].Beijing: China medical science press， 2002: 362.
[6]	Therasse P， Arbuck SG， Eisenhauer EA， et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer， National Cancer Institute of the United States， National Cancer Institute of Canada[J]. J Natl Cancer Inst， 2000， 92(3): 205-216.
[7]	Patt YZ， Lee FC， Liebmann JE， et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase Ⅱ trial results[J]. Am J Clin Oncol， 2007， 30(4):350-357.